Venturi Wealth Management LLC Invests $271,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

Venturi Wealth Management LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 9,000 shares of the biopharmaceutical company's stock, valued at approximately $271,000.

Other institutional investors have also made changes to their positions in the company. Creative Planning boosted its stake in TG Therapeutics by 19.2% in the 3rd quarter. Creative Planning now owns 55,832 shares of the biopharmaceutical company's stock worth $1,306,000 after purchasing an additional 8,993 shares during the period. Vontobel Holding Ltd. purchased a new stake in shares of TG Therapeutics in the third quarter valued at $222,000. Blue Trust Inc. boosted its position in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 849 shares during the period. Raymond James & Associates grew its holdings in shares of TG Therapeutics by 35.9% during the third quarter. Raymond James & Associates now owns 170,160 shares of the biopharmaceutical company's stock valued at $3,980,000 after buying an additional 44,972 shares in the last quarter. Finally, Private Advisor Group LLC raised its position in TG Therapeutics by 3.9% during the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company's stock valued at $337,000 after buying an additional 542 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TGTX has been the subject of a number of research reports. JPMorgan Chase & Co. raised their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a report on Wednesday, January 15th. TD Cowen started coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a "buy" rating and a $50.00 price objective on the stock. StockNews.com downgraded shares of TG Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, January 31st. Finally, The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, TG Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Stock Down 6.0 %

NASDAQ TGTX traded down $1.86 during trading on Monday, reaching $29.02. The company's stock had a trading volume of 2,953,913 shares, compared to its average volume of 2,189,992. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $4.52 billion, a PE ratio of -290.17 and a beta of 2.26. TG Therapeutics, Inc. has a 1-year low of $12.93 and a 1-year high of $36.84. The business has a 50-day moving average price of $30.96 and a 200-day moving average price of $27.90.

Insider Activity

In other news, CFO Sean A. Power sold 10,021 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 10.50% of the stock is owned by insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.